Qué financiamos (solo en inglés)

Funded projects
1,320+
Men's Health Partners
20
Countries
20
We work closely with our global men's health partners to ensure collaboration, transparency and accountability for every project we fund. We monitor this through report cards which detail what we seek to achieve, key measures and the impact.
Prostate Cancer
"Together with the brightest minds in research, we aim to achieve significant breakthroughs in the hope of beating prostate cancer. Our disruptive funding approach identifies revolutionary ways to accelerate health outcomes by creating strong, global collaborative teams." Dr. Colleen Nelson, Global Scientific Chair.
Men's Health
"One Mo can help change the face of men’s health through the powerful conversations created globally during Movember. Men have the chance to confidently discuss men’s health with people around them, resulting in men taking action early, helping change and save lives." Paul Villanti, Executive Director, Programmes
Mental health and suicide prevention
“The number of men taking their own lives around the world is one of the biggest challenges of our time. Movember is working to ensure all men and boys look after their mental health and are comfortable to seek help when they’re struggling.”
Brendan Maher, Global Director, Mental Health and Suicide Prevention.
Testicular Cancer
“Despite being the 2nd most common cancer in young men, testicular cancer is often a forgotten cancer due to early detection and treatment. Our projects look at underinvested areas such as improving access to healthcare services and treatment options for relapse” Paul Villanti, Executive Director, Programmes.

Identifying Genes That Cause Testicular Cancer

Movember Funding to Date

GBP 1,050,000

What we seek to achieve

By using advanced genetic technologies including Next Generation Sequencing and Array SNP Genotyping, the aim of the project is to discover and better understand genetic factors which are linked to the development of testicular cancer.

Country
United Kingdom
Implemented by
The Institute of Cancer Research
Project start date
April 2013
Project Status
Completed July 2016

About the project

This research is being undertaken by Dr Clare Turnbull and her team at The Institute of Cancer Research (ICR), UK.

At ICR the testicular cancer research team have assembled blood samples and tumour samples from a significant series of men with testicular cancer. This is the largest collection of samples from men with testicular cancer in the world.

The team are using several advanced genetic technologies to study the genetic sequence of these men. These include “Next Generation Sequencing” and “Array SNP genotyping”. Next Generation Sequencing of the “exome” involves studying the full code of all genes. This totals about 20,000 genes, which equates to approximately 30 million bases of DNA. However, the genes only account for less than 2% of the human genome, and it is known that the remaining 98% is important but it is not yet well understood. Array SNP genotyping is another approach to studying the genetic code and enables us to study at scale genetic variants outside of the genes. Array SNP genotyping involves analysing hundreds of thousands of selected genetic variants (SNPs) which have been assembled onto a “SNP array”.  

The research team use the data they generate to compare patterns of genetic variants:
(i) between men with and without testicular cancer
(ii) across families with multiple cases of testicular cancer 
(iii) between the blood and the tumour of men with testicular cancer.

The research team will analyse the combined data to identify the specific genetic variants linked with development of testicular cancer. In all cases, large experiments are needed to distinguish ‘signal’ from ‘noise’, that is to identify the biologically important genetic changes from all of the innocent ‘spelling variations’ in the genes.

Complex analyses of these data integrated with other biological data (bioinformatics), studies of the patterns of disease within families and populations (genetic epidemiology) and mathematical modelling best enable us to understand the relevance of the genetic signals we see in our experiments.

There are two main reasons why identification of the genetic variants that underlie the development of testicular cancer is important:
(i) to enable development of genetic tests to better understand which men are at high risk of developing testicular cancer and/or, once a man develops testicular cancer, to better predict the behaviour of tumours 
(ii) to enable better biological understanding of how and why the disease develops, which may in turn facilitate better and more targeted treatment.

Prostate Cancer Research Alliance

The Program will fund research that leverages Australia's existing strengths in prostate cancer biomedical research to deliver outcomes that can be translated into clinical practice within the next 5 to 7 years.

Find out more
Australia
AUD 12,150,000
USA - Mass market, multi-platform public media documentary series & campaign

This project uses a mass market, multi dimensional campaigns to shift populations understanding, attitudes and intentions and ultimately improve health outcomes on a large scale. Focusing on Youth Mental Health we will be working in partnership with PBS to deliver a documentary series supported with educational, digital and in person elements delivered across the USA.

Find out more
United States
USD 2,400,000
Ironman Registry

IRONMAN is an international, population-based registry of 5,000 men with advanced prostate cancer across ten countries. It seeks to understand clinical outcomes associated with management of advanced prostate cancer and understand the biological and clinical diversity of the disease.

Find out more
South Africa
Global Funding AUD equivalent 18,905,25
Ironman Registry

IRONMAN is an international, population-based registry of 5,000 men with advanced prostate cancer across ten countries. It seeks to understand clinical outcomes associated with management of advanced prostate cancer and understand the biological and clinical diversity of the disease.

Find out more
Spain
Global Funding AUD equivalent 18,905,25
Ironman Registry

IRONMAN is an international, population-based registry of 5,000 men with advanced prostate cancer across ten countries. It seeks to understand clinical outcomes associated with management of advanced prostate cancer and understand the biological and clinical diversity of the disease.

Find out more
Ireland
Global Funding AUD equivalent 18,905,25
Ironman Registry

IRONMAN is an international, population-based registry of 5,000 men with advanced prostate cancer across ten countries. It seeks to understand clinical outcomes associated with management of advanced prostate cancer and understand the biological and clinical diversity of the disease.

Find out more
Switzerland
Global Funding AUD equivalent 18,905,25
Ironman Registry

IRONMAN is an international, population-based registry of 5,000 men with advanced prostate cancer across ten countries. It seeks to understand clinical outcomes associated with management of advanced prostate cancer and understand the biological and clinical diversity of the disease.

Find out more
Sweden
Global Funding AUD equivalent 18,905,25
Ironman Registry

IRONMAN is an international, population-based registry of 5,000 men with advanced prostate cancer across ten countries. It seeks to understand clinical outcomes associated with management of advanced prostate cancer and understand the biological and clinical diversity of the disease.

Find out more
United States
Global Funding AUD equivalent 18,905,25
Ironman Registry

IRONMAN is an international, population-based registry of 5,000 men with advanced prostate cancer across ten countries. It seeks to understand clinical outcomes associated with management of advanced prostate cancer and understand the biological and clinical diversity of the disease.

Find out more
United Kingdom
Global Funding AUD equivalent 18,905,25
Ironman Registry

IRONMAN is an international, population-based registry of 5,000 men with advanced prostate cancer across 15 countries. It seeks to understand clinical outcomes associated with management of advanced prostate cancer and understand the biological and clinical diversity of the disease.

Find out more
Canada
Global Funding AUD equivalent 18,905,25
Ironman Registry

IRONMAN is an international, population-based registry of 5,000 men with advanced prostate cancer across 15 countries. It seeks to understand clinical outcomes associated with management of advanced prostate cancer and understand the biological and clinical diversity of the disease.

Find out more
Australia
Global Funding AUD equivalent 18,905,25
Movember – Distinguished Gentleman’s Ride Clinician Scientist Award - 2017

Clinician Scientist Awards aim to support outstanding, clinically qualified professionals who have gained a PhD in health research, to combine their clinical career with a research career and establish themselves as independent researchers in the field of prostate cancer.

Find out more
Australia
-
TrueNTH Global Registry

Established in 2017 and operating across 17 countries, the TrueNTH Global Registry is an international project that aims to improve the physical and mental health of men with prostate cancer. Clinicians and hospitals contributing data to TrueNTH Global Registry receive regular, risk-adjusted reports on their patients’ health outcomes as compared to other clinicians and hospitals globally. This will support improvement in clinical practice and patient outcomes over time.

Find out more
Australia
Global funding AUD equivalent 20,336,828
Canadian Men's Health & Wellbeing Innovation Challenge

To support the implementation of outside the box proof of concept ideas that disrupt long held assumptions/myths about men and their health which will encourage doing things differently and ultimately lead to improved health outcomes.

Find out more
Canada
CAD 1,923,149
Prostate Cancer Outcomes - Registry Australia and New Zealand

The Prostate Cancer Outcomes Registry of Australia and New Zealand (PCOR-ANZ) is a clinical quality registry collecting data on the diagnosis, clinical care and outcomes for men living with prostate cancer across Australia and New Zealand.

Find out more
Australia
Global funding AUD equivalent 22,397,860
TrueNTH Testicular Cancer

TrueNTH Testicular Cancer is a website, optimised for mobile devices, that aims to bring resources to men who are facing a diagnosis and early treatment for testicular cancer. We have created a resource that delivers information to men to help them navigate the early stages of treatment along with the functionality to connect with a survivor who has lived through the same experience to facilitate peer support and a capacity to seek advice from experts in the field relating to the Testicular Cancer Journey. 

Find out more
Australia
AUD 1,180,594
>
Page 1 of 33